

# Pablo Martínez-Martín

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7581964/publications.pdf>

Version: 2024-02-01

450  
papers

29,590  
citations

7568

77  
h-index

7518

151  
g-index

486  
all docs

486  
docs citations

486  
times ranked

19868  
citing authors

#	ARTICLE	IF	CITATIONS
1	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008, 23, 2129-2170.	3.9	4,796
2	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. <i>Movement Disorders</i> , 2007, 22, 41-47.	3.9	1,097
3	International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study. <i>Movement Disorders</i> , 2006, 21, 916-923.	3.9	865
4	The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. <i>Movement Disorders</i> , 2007, 22, 1901-1911.	3.9	838
5	The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 399-406.	3.9	744
6	Unified Parkinson's disease rating scale characteristics and structure. <i>Movement Disorders</i> , 1994, 9, 76-83.	3.9	658
7	Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients. <i>Movement Disorders</i> , 2007, 22, 1623-1629.	3.9	461
8	The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: An international study using the nonmotor symptoms questionnaire. <i>Movement Disorders</i> , 2010, 25, 704-709.	3.9	342
9	Parkinson's disease: The non-motor issues. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 717-723.	2.2	313
10	Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. <i>Neurology</i> , 2005, 64, 1586-1591.	1.1	306
11	Parkinson's disease sleep scale-validation of the revised version PDSS-2. <i>Movement Disorders</i> , 2011, 26, 644-652.	3.9	296
12	Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2008, 23, 2004-2014.	3.9	285
13	Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. <i>Brain</i> , 2004, 127, 2348-2359.	7.6	244
14	Health-related quality-of-life scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2011, 26, 2371-2380.	3.9	234
15	Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. <i>Movement Disorders</i> , 2009, 24, 1468-1474.	3.9	233
16	Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 50-54.	2.2	216
17	International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease. <i>Neurology</i> , 2009, 73, 1584-1591.	1.1	213
18	Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2016, 31, 1342-1355.	3.9	212

#	ARTICLE	IF	CITATIONS
19	Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. <i>Journal of Neurology</i> , 2012, 259, 1639-1647.	3.6	211
20	Caregiver burden in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 924-931.	3.9	208
21	Anxiety rating scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2008, 23, 2015-2025.	3.9	208
22	The non-motor symptom complex of Parkinson's disease: A comprehensive assessment is essential. <i>Current Neurology and Neuroscience Reports</i> , 2005, 5, 275-283.	4.2	203
23	Euro-IMPACT: A multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 510-516.	3.9	203
24	Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 805-822.	3.9	193
25	King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation. <i>Movement Disorders</i> , 2015, 30, 1623-1631.	3.9	189
26	Clinical subtypes of Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 51-58.	3.9	186
27	A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 388-395.	1.9	178
28	Factors Associated With Loneliness of Noninstitutionalized and Institutionalized Older Adults. <i>Journal of Aging and Health</i> , 2011, 23, 177-194.	1.7	174
29	The Parkinson Anxiety Scale (PAS): Development and validation of a new anxiety scale. <i>Movement Disorders</i> , 2014, 29, 1035-1043.	3.9	173
30	Expanded and independent validation of the Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS). <i>Journal of Neurology</i> , 2013, 260, 228-236.	3.6	169
31	Burden, perceived health status, and mood among caregivers of Parkinson's disease patients. <i>Movement Disorders</i> , 2008, 23, 1673-1680.	3.9	166
32	Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 629-634.	2.2	166
33	Anxiety rating scales in Parkinson's disease: A validation study of the Hamilton anxiety rating scale, the Beck anxiety inventory, and the hospital anxiety and depression scale. <i>Movement Disorders</i> , 2011, 26, 407-415.	3.9	158
34	Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1133-1144.	2.2	156
35	Quantitation of non-motor symptoms in Parkinson's disease. <i>European Journal of Neurology</i> , 2008, 15, 2-8.	3.3	154
36	An introduction to the concept of "quality of life in Parkinson's disease". <i>Journal of Neurology</i> , 1998, 245, S2-S6.	3.6	151

#	ARTICLE	IF	CITATIONS
37	Dystonia rating scales: Critique and recommendations. <i>Movement Disorders</i> , 2013, 28, 874-883.	3.9	150
38	Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 372-377.	3.9	148
39	Adherence to antiparkinson medication in a multicenter European study. <i>Movement Disorders</i> , 2009, 24, 826-832.	3.9	146
40	Symptomatology and markers of anxiety disorders in Parkinson's disease: A cross-sectional study. <i>Movement Disorders</i> , 2011, 26, 484-492.	3.9	142
41	Social robots in advanced dementia. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 133.	3.4	142
42	GREATER RISK OF ALZHEIMER'S DISEASE IN OLDER ADULTS WITH INSOMNIA. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 559-562.	2.6	139
43	Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018, 33, 208-218.	3.9	138
44	Detection of varicella-zoster virus-specific DNA sequences in cerebrospinal fluid from patients with acute aseptic meningitis and no cutaneous lesions. <i>Journal of Medical Virology</i> , 1994, 43, 331-335.	5.0	136
45	The importance of non-motor disturbances to quality of life in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2011, 310, 12-16.	0.6	129
46	Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease – Clinical practice recommendations. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1023-1030.	2.2	126
47	EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 353-365.	3.9	126
48	Task force report: Scales for screening and evaluating tremor: Critique and recommendations. <i>Movement Disorders</i> , 2013, 28, 1793-1800.	3.9	124
49	Quality of life of caregivers in Parkinson's disease. <i>Quality of Life Research</i> , 2005, 14, 463-472.	3.1	122
50	Prevalence of dementia and major dementia subtypes in Spanish populations: A reanalysis of dementia prevalence surveys, 1990-2008. <i>BMC Neurology</i> , 2009, 9, 55.	1.8	115
51	Quality of life and burden in caregivers for patients with Parkinson's disease: concepts, assessment and related factors. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 221-230.	1.4	112
52	Rotigotine and specific non-motor symptoms of Parkinson's disease: Post hoc analysis of RECOVER. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 660-665.	2.2	112
53	The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations. <i>Movement Disorders</i> , 2016, 31, 1080-1094.	3.9	112
54	Chronic Subcutaneous Infusion Therapy with Apomorphine in Advanced Parkinson's Disease Compared to Conventional Therapy: A Real Life Study of Non Motor Effect. <i>Journal of Parkinson's Disease</i> , 2011, 1, 197-203.	2.8	107

#	ARTICLE	IF	CITATIONS
55	Active ageing and quality of life: factors associated with participation in leisure activities among institutionalized older adults, with and without dementia. <i>Aging and Mental Health</i> , 2015, 19, 1031-1041.	2.8	105
56	Prolonged-release oxycodone+naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2015, 14, 1161-1170.	10.2	102
57	Wearing+off scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2011, 26, 2169-2175.	3.9	101
58	The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography. <i>Journal of the Neurological Sciences</i> , 2006, 248, 158-162.	0.6	99
59	A short psychosocial questionnaire for patients with Parkinson's disease. <i>Journal of Clinical Epidemiology</i> , 2003, 56, 61-67.	5.0	97
60	Guidelines for the diagnosis and management of neurological complications of HIV infection. <i>European Journal of Neurology</i> , 2004, 11, 297-304.	3.3	97
61	Anxiety and depression: Main determinants of health-related quality of life in Brazilian patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 102-108.	2.2	96
62	A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need. <i>PLoS ONE</i> , 2013, 8, e57221.	2.5	95
63	Quality of life in Parkinson+™s disease: validation study of the PDQ-39 Spanish version. <i>Journal of Neurology</i> , 1998, 245, S34-S38.	3.6	94
64	Parkinson's Disease Subtypes Identified from Cluster Analysis of Motor and Non-motor Symptoms. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 301.	3.4	94
65	Non-motor symptoms of Parkinson's disease A review+from the past. <i>Journal of the Neurological Sciences</i> , 2014, 338, 30-33.	0.6	93
66	The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: A simple grading system. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 287-291.	2.2	93
67	Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2017, 373, 173-178.	0.6	93
68	Residential satisfaction, sense of belonging and loneliness among older adults living in the community and in care facilities. <i>Health and Place</i> , 2011, 17, 1183-1190.	3.3	92
69	Systematic review of severity scales and screening instruments for tics: Critique and recommendations. <i>Movement Disorders</i> , 2017, 32, 467-473.	3.9	92
70	Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2010, 25, 1131-1142.	3.9	90
71	Non-motor outcomes depend on location of neurostimulation in Parkinson+™s disease. <i>Brain</i> , 2019, 142, 3592-3604.	7.6	90
72	International validation of a behavioral scale in Parkinson's disease without dementia. <i>Movement Disorders</i> , 2015, 30, 705-713.	3.9	88

#	ARTICLE	IF	CITATIONS
73	Disability Rating Scales in Parkinson's Disease: Critique and Recommendations. <i>Movement Disorders</i> , 2016, 31, 1455-1465.	3.9	87
74	Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease. <i>Brain Stimulation</i> , 2016, 9, 78-85.	1.6	86
75	Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease. <i>European Journal of Neurology</i> , 2012, 19, 105-113.	3.3	84
76	The SCOPA-Motor Scale for assessment of Parkinson's disease is a consistent and valid measure. <i>Journal of Clinical Epidemiology</i> , 2005, 58, 674-679.	5.0	82
77	Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale. <i>European Journal of Neurology</i> , 2015, 22, 37-43.	3.3	82
78	Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 2183-2191.	3.9	81
79	Determinants of quality of life in Brazilian patients with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1408-1415.	3.9	80
80	SCOPA-sleep and PDSS: Two scales for assessment of sleep disorder in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1681-1688.	3.9	80
81	Infections of the Nervous System Caused by Varicella-Zoster Virus: A Review. <i>Intervirology</i> , 1997, 40, 72-84.	2.8	79
82	Motor laterality asymmetry and nonmotor symptoms in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 70-75.	3.9	79
83	Anxiety and motor fluctuations in Parkinson's disease: A cross-sectional observational study. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 1084-1088.	2.2	79
84	Postural instability and gait are associated with severity and prognosis of Parkinson disease. <i>Neurology</i> , 2016, 86, 2243-2250.	1.1	78
85	A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 27-32.	2.2	77
86	Relationship between sleep disorders and other non-motor symptoms in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1152-1155.	2.2	76
87	Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: An international multicenter study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1231-1235.	2.2	76
88	A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. <i>European Journal of Neurology</i> , 2016, 23, 1255-1261.	3.3	76
89	Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 757-765.	3.9	75
90	Independent validation of the scales for outcomes in Parkinson's disease-autonomic (SCOPA-AUT). <i>European Journal of Neurology</i> , 2010, 17, 194-201.	3.3	74

#	ARTICLE	IF	CITATIONS
91	What is quality of life and how do we measure it? Relevance to Parkinson's disease and movement disorders. <i>Movement Disorders</i> , 2017, 32, 382-392.	3.9	73
92	Impact of Fatigue in Parkinson's Disease: The Fatigue Impact Scale for Daily Use (D-FIS). <i>Quality of Life Research</i> , 2006, 15, 597-606.	3.1	71
93	Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 151-157.	2.2	71
94	Global versus factor-related impression of severity in Parkinson's disease: A new clinimetric index (CISI-PD). <i>Movement Disorders</i> , 2006, 21, 208-214.	3.9	69
95	Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 421-430.	3.9	69
96	Psychometric attributes of the Hospital Anxiety and Depression Scale in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 519-525.	3.9	68
97	Efficacy and safety of pallidal stimulation in primary dystonia: results of the Spanish multicentric study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 65-69.	1.9	67
98	COPPADIS-2015 (COhort of Patients with Parkinson's Disease in Spain, 2015), a global "clinical evaluations, serum biomarkers, genetic studies and neuroimaging" prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. <i>BMC Neurology</i> , 2016, 16, 26.	1.8	66
99	Pain in Parkinson's disease: facts and uncertainties. <i>European Journal of Neurology</i> , 2018, 25, 917.	3.3	66
100	Efficacy and Safety of Metamizol vs. Acetylsalicylic Acid in Patients With Moderate Episodic Tension-Type Headache: A Randomized, Double-Blind, Placebo- and Active-Controlled, Multicentre Study. <i>Cephalalgia</i> , 2001, 21, 604-610.	3.9	65
101	Measurement properties of the Community Wellbeing Index in older adults. <i>Quality of Life Research</i> , 2011, 20, 733-743.	3.1	65
102	Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 536-544.	1.5	65
103	Burden and health-related quality of life among caregivers of Brazilian Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 943-948.	2.2	64
104	Non-motor symptoms burden in treated and untreated early Parkinson's disease patients: argument for non-motor subtypes. <i>European Journal of Neurology</i> , 2015, 22, 1145-1150.	3.3	64
105	Clinical Assessments in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 129-182.	2.0	63
106	A New Clinical Tool for Gait Evaluation in Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 1997, 20, 183-194.	0.7	61
107	Dementia associated with Parkinson's disease: Applying the Movement Disorder Society Task Force criteria. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 621-624.	2.2	61
108	Oral and Infusion Levodopa-Based Strategies for Managing Motor Complications in Patients with Parkinson's Disease. <i>CNS Drugs</i> , 2010, 24, 119-129.	5.9	60

#	ARTICLE	IF	CITATIONS
109	The Movement Disorder Society Nonmotor Rating Scale: Initial Validation Study. <i>Movement Disorders</i> , 2020, 35, 116-133.	3.9	59
110	Discrimination Analysis of Blood Plasma Associated with Alzheimer's Disease Using Vibrational Spectroscopy. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 911-920.	2.6	57
111	Pallidotomy and quality of life in patients with parkinson's disease: An early study. <i>Movement Disorders</i> , 2000, 15, 65-70.	3.9	56
112	Surgery and Risk of Sporadic Creutzfeldt-Jakob Disease in Denmark and Sweden: Registry-Based Case-Control Studies. <i>Neuroepidemiology</i> , 2008, 31, 229-240.	2.3	56
113	The clinical impression of severity index for Parkinson's disease: International validation study. <i>Movement Disorders</i> , 2009, 24, 211-217.	3.9	56
114	Estimating the direct and indirect costs associated with Parkinson's disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 889-911.	1.4	56
115	The long-term direct and indirect economic burden among Parkinson's disease caregivers in the United States. <i>Movement Disorders</i> , 2019, 34, 236-245.	3.9	56
116	The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 889-893.	2.2	55
117	Modeling depression in Parkinson disease. <i>Neurology</i> , 2013, 81, 1036-1043.	1.1	55
118	Double-blind Randomized Trial of tDCS Versus Sham in Parkinson Patients With Mild Cognitive Impairment Receiving Cognitive Training. <i>Brain Stimulation</i> , 2015, 8, 1223-1225.	1.6	55
119	Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 270-279.	3.9	55
120	Independent validation of SCOPA's psychosocial and metric properties of the PDQ-39 Brazilian version. <i>Movement Disorders</i> , 2007, 22, 91-98.	3.9	54
121	Consensus on the Definition of Advanced Parkinson's Disease: A Neurologists-Based Delphi Study (CEPA Study). <i>Parkinson's Disease</i> , 2017, 2017, 1-8.	1.1	53
122	Non-motor outcomes of subthalamic stimulation in Parkinson's disease depend on location of active contacts. <i>Brain Stimulation</i> , 2018, 11, 904-912.	1.6	53
123	Health-related quality of life evaluation by proxy in Parkinson's disease: Approach using PDQ-8 and EuroQoL-5D. <i>Movement Disorders</i> , 2004, 19, 312-318.	3.9	52
124	Quantitative assessment of non-motor fluctuations in Parkinson's disease using the Non-Motor Symptoms Scale (NMSS). <i>Journal of Neural Transmission</i> , 2015, 122, 1673-1684.	2.8	52
125	Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations. <i>Movement Disorders</i> , 2021, 36, 283-297.	3.9	52
126	Aseptic Meningitis Due to Varicella-Zoster Virus: Serum Antibody Levels and Local Synthesis of Specific IgG, IgM, and IgA. <i>Journal of Infectious Diseases</i> , 1987, 155, 959-967.	4.0	51



#	ARTICLE	IF	CITATIONS
127	Evaluation of the Short Parkinson's Evaluation Scale. <i>Clinical Neuropharmacology</i> , 1997, 20, 322-337.	0.7	51
128	Intrajejunal Levodopa Versus Conventional Therapy in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2012, 35, 205-207.	0.7	51
129	Curcumin/Melatonin Hybrid 5-(4-Hydroxy-phenyl)-3-oxo-pentanoic Acid [2-(5-Methoxy-1 <i>H</i> -indol-3-yl)-ethyl]-amide Ameliorates AD-Like Pathology in the APP/PS1 Mouse Model. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1393-1399.	3.5	51
130	Drooling in Parkinson's Disease: Prevalence and Progression from the Non-motor International Longitudinal Study. <i>Dysphagia</i> , 2020, 35, 955-961.	1.8	51
131	Unveiling relevant non-motor Parkinson's disease severity symptoms using a machine learning approach. <i>Artificial Intelligence in Medicine</i> , 2013, 58, 195-202.	6.5	50
132	Metric attributes of the unified Parkinson's disease rating scale 3.0 battery: Part I, feasibility, scaling assumptions, reliability, and precision. <i>Movement Disorders</i> , 2006, 21, 1182-1188.	3.9	49
133	Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2019, 34, 791-798.	3.9	49
134	The Non-motor Symptoms Scale in Parkinson's disease: Validation and use. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 3-12.	2.1	49
135	Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS). <i>Multiple Sclerosis Journal</i> , 2007, 13, 645-651.	3.0	48
136	Depression and anxiety in Parkinson disease. <i>Nature Reviews Neurology</i> , 2010, 6, 243-245.	10.1	48
137	Rapidly Progressive Alzheimer's Disease: A Multicenter Update. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 751-756.	2.6	48
138	A Review of Scales to Evaluate Sleep Disturbances in Movement Disorders. <i>Frontiers in Neurology</i> , 2018, 9, 369.	2.4	48
139	Patients', doctors', and caregivers' assessment of disability using the UPDRS-ADL section: Are these ratings interchangeable?. <i>Movement Disorders</i> , 2003, 18, 985-992.	3.9	47
140	Review of Diagnostic Instruments for the Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED): Critique and Recommendations. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 1343-1349.	2.6	47
141	Intrathecal synthesis of IgG antibodies to varicella-zoster virus in two cases of acute aseptic meningitis syndrome with no cutaneous lesions. <i>Journal of Medical Virology</i> , 1985, 16, 201-209.	5.0	46
142	Psychometric properties of the International Wellbeing Index in community-dwelling older adults. <i>International Psychogeriatrics</i> , 2011, 23, 161-169.	1.0	46
143	Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients. <i>European Journal of Neurology</i> , 2014, 21, 519-524.	3.3	46
144	Rating Scales for Pain in Parkinson's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 527-537.	1.5	46

#	ARTICLE	IF	CITATIONS
145	Advanced Parkinson's or "complex phase" Parkinson's disease? Re-evaluation is needed. <i>Journal of Neural Transmission</i> , 2017, 124, 1529-1537.	2.8	46
146	Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 83-89.	2.2	46
147	Longitudinal Metric Properties of Disability Rating Scales for Parkinson's Disease. <i>Value in Health</i> , 2006, 9, 386-393.	0.3	45
148	Factor analysis of the Hamilton Depression Rating Scale in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 142-146.	2.2	45
149	A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement. <i>Journal of Parkinson's Disease</i> , 2017, 7, 533-543.	2.8	45
150	Parkinson's disease sleep scale: Validation study of a Spanish version. <i>Movement Disorders</i> , 2004, 19, 1226-1232.	3.9	44
151	The CAREQOL-MS was a useful instrument to measure caregiver quality of life in multiple sclerosis. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 675-686.	5.0	44
152	Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2016, 31, 1466-1478.	3.9	44
153	Drug-induced tardive syndromes. <i>Parkinsonism and Related Disorders</i> , 1999, 5, 59-65.	2.2	43
154	Genetic Cross-Interaction between APOE and PRNP in Sporadic Alzheimer's and Creutzfeldt-Jakob Diseases. <i>PLoS ONE</i> , 2011, 6, e22090.	2.5	43
155	Health-related quality of life as an outcome variable in Parkinson's disease. <i>Therapeutic Advances in Neurological Disorders</i> , 2012, 5, 105-117.	3.5	43
156	Non-Motor Symptoms in Patients Suffering from Motor Neuron Diseases. <i>Frontiers in Neurology</i> , 2016, 7, 117.	2.4	43
157	The Parkinson's disease "diary": Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019, 34, 676-681.	3.9	43
158	Health status and well-being of older adults living in the community and in residential care settings: Are differences influenced by age?. <i>Aging and Mental Health</i> , 2012, 16, 884-891.	2.8	41
159	Non-Motor Symptoms Profile and Burden in Drug Naïve Versus Long-Term Parkinson's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2014, 4, 541-547.	2.8	41
160	EQ-5D rated by proxy in institutionalized older adults with dementia: Psychometric pros and cons. <i>Geriatrics and Gerontology International</i> , 2014, 14, 346-353.	1.5	41
161	Perceptions of symptoms and expectations of advanced therapy for Parkinson's disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson's disease (PRO-APD). <i>Health and Quality of Life Outcomes</i> , 2014, 12, 11.	2.4	41
162	Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 373-378.	3.9	41

#	ARTICLE	IF	CITATIONS
163	Validation of the "QUICK" questionnaire: A tool for diagnosis of "wearing-off" in patients with Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 830-836.	3.9	40
164	Non-motor symptom burden is strongly correlated to motor complications in patients with Parkinson's disease. <i>European Journal of Neurology</i> , 2020, 27, 1210-1223.	3.3	40
165	Most of the Quality of Life in Essential Tremor Questionnaire (QUEST) psychometric properties resulted in satisfactory values. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 767-773.	5.0	39
166	Quality of life outcome after subthalamic stimulation in Parkinson's disease depends on age. <i>Movement Disorders</i> , 2018, 33, 99-107.	3.9	39
167	Extending levodopa action. <i>Neurology</i> , 1998, 50, S27-32; discussion S44-8.	1.1	38
168	Night-time sleep in Parkinson's disease – the potential use of Parkinson's KinetiGraph: a prospective comparative study. <i>European Journal of Neurology</i> , 2016, 23, 1275-1288.	3.3	38
169	Rating scales for cognition in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018, 33, 187-195.	3.9	38
170	Nonmotor symptoms and focal cervical dystonia: Observations from 102 patients. <i>Basal Ganglia</i> , 2014, 4, 117-120.	0.3	37
171	Effect of heat waves on morbidity and mortality due to Parkinson's disease in Madrid: A time-series analysis. <i>Environment International</i> , 2016, 89-90, 1-6.	10.0	37
172	Composite rating scales. <i>Journal of the Neurological Sciences</i> , 2010, 289, 7-11.	0.6	36
173	Prevalence of disability in a composite ≥75 year-old population in Spain: A screening survey based on the International Classification of Functioning. <i>BMC Public Health</i> , 2011, 11, 176.	2.9	36
174	Components and determinants of quality of life in community-dwelling older adults. <i>European Journal of Ageing</i> , 2012, 9, 255-263.	2.8	36
175	Robotherapy with Dementia Patients. <i>International Journal of Advanced Robotic Systems</i> , 2013, 10, 10.	2.1	36
176	Importance of nondopaminergic features in evaluating disease severity of Parkinson disease. <i>Neurology</i> , 2014, 82, 412-418.	1.1	36
177	Short-term quality of life after subthalamic stimulation depends on non-motor symptoms in Parkinson's disease. <i>Brain Stimulation</i> , 2018, 11, 867-874.	1.6	36
178	Beneficial nonmotor effects of subthalamic and pallidal neurostimulation in Parkinson's disease. <i>Brain Stimulation</i> , 2020, 13, 1697-1705.	1.6	36
179	A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: results at the 36-month follow-up. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 687-694.	1.9	36
180	Clinical assessment of nocturnal disability in Parkinson's disease. <i>Neurology</i> , 2004, 63, S17-20.	1.1	36

#	ARTICLE	IF	CITATIONS
181	Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis. PLoS ONE, 2015, 10, e0145310.	2.5	35
182	Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson's Disease. CNS Drugs, 2015, 29, 397-413.	5.9	35
183	Prevalence of Non-Motor Symptoms and Non-Motor Fluctuations in Parkinson's Disease Using the <sc>MDS&NMS</sc>. Movement Disorders Clinical Practice, 2021, 8, 231-239.	1.5	35
184	Validation of the self-administered version of the international Restless Legs Syndrome study group severity rating scale " The sRLS. Sleep Medicine, 2019, 54, 94-100.	1.6	34
185	Self-perceived health status in older adults: regional and sociodemographic inequalities in Spain. Revista De Saude Publica, 2012, 46, 310-319.	1.7	32
186	Rating scales and questionnaires for assessment of sleep disorders in Parkinson's disease: what they inform about?. Journal of Neural Transmission, 2014, 121, 33-40.	2.8	32
187	Anxiety Has Specific Syndromal Profiles in Parkinson Disease: A Data-Driven Approach. American Journal of Geriatric Psychiatry, 2014, 22, 1410-1417.	1.2	32
188	Review of Severity Rating Scales for Restless Legs Syndrome: Critique and Recommendations. Movement Disorders Clinical Practice, 2014, 1, 317-324.	1.5	32
189	Validation study of the hoehn and yahr scale included in the MDS&UPDRS. Movement Disorders, 2018, 33, 651-652.	3.9	32
190	<sc>COPPADIS</sc> 2015 (<sc>CO</sc>hort of Patients with Parkinson's <sc>DI</sc>sease in) Tj ETQq0 0 0 rgBT /Overlock 1000 subjects included. Results from the baseline evaluation. European Journal of Neurology, 2019, 26, 1399-1407.	3.3	32
191	Dementia in long-term Parkinson's disease patients: a multicentre retrospective study. Npj Parkinson's Disease, 2020, 6, 2.	5.3	32
192	Exploring Requirements and Alternative Pet Robots for Robot Assisted Therapy with Older Adults with Dementia. Lecture Notes in Computer Science, 2013, , 104-115.	1.3	32
193	Assessing autonomic symptoms of Parkinson's disease with the SCOPA&AUT: a new perspective from Rasch analysis. European Journal of Neurology, 2010, 17, 273-279.	3.3	31
194	Alzheimer Center Reina Sofia Foundation: Fighting the Disease and Providing Overall Solutions. Journal of Alzheimer's Disease, 2010, 21, 337-348.	2.6	31
195	Clinical and Anatomical Correlates of Gait Dysfunction in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, 495-505.	2.6	31
196	Design, measures and sample characteristics of the CadeViMa-Spain survey on quality of life in community-dwelling older adults. International Psychogeriatrics, 2012, 24, 425-438.	1.0	31
197	Quality of life in older people with dementia: A multilevel study of individual attributes and residential care center characteristics. Geriatrics and Gerontology International, 2015, 15, 104-110.	1.5	31
198	Pilot Study of the International Parkinson and Movement Disorder Society's sponsored Non-motor Rating Scale (MDS&NMS). Movement Disorders Clinical Practice, 2019, 6, 227-234.	1.5	31

#	ARTICLE	IF	CITATIONS
199	Remote Monitoring of Treatment Response in Parkinson's Disease: The Habit of Typing on a Computer. <i>Movement Disorders</i> , 2019, 34, 1488-1495.	3.9	31
200	Psychometric attributes of the SCOPA-COG Brazilian version. <i>Movement Disorders</i> , 2008, 23, 81-87.	3.9	30
201	Comprehensive grading of Parkinson's disease using motor and non-motor assessments: addressing a key unmet need. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 41-50.	2.8	30
202	Rasch analysis of the hospital anxiety and depression scale in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 526-532.	3.9	29
203	Caregivers' estimation of patients' quality of life (QoL) in Alzheimer's disease (AD): An approach using the ADRQL. <i>Archives of Gerontology and Geriatrics</i> , 2011, 53, 13-18.	3.0	29
204	The Q10 questionnaire for detection of wearing-off phenomena in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 382-385.	2.2	29
205	Rating of daytime and nighttime symptoms in RLS: validation of the RLS-6 scale of restless legs syndrome/Willis-Ekbom disease. <i>Sleep Medicine</i> , 2016, 20, 116-122.	1.6	29
206	Non-Motor Symptoms Assessed by Non-Motor Symptoms Questionnaire and Non-Motor Symptoms Scale in Parkinson's Disease in Selected Asian Populations. <i>Neuroepidemiology</i> , 2017, 49, 1-17.	2.3	29
207	Non motor symptoms in progressive supranuclear palsy: prevalence and severity. <i>Npj Parkinson's Disease</i> , 2017, 3, 35.	5.3	29
208	Identifying and responding to fatigue and apathy in Parkinson's disease: a review of current practice. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 477-495.	2.8	29
209	Metric attributes of the unified Parkinson's disease rating scale 3.0 battery: Part II, construct and content validity. <i>Movement Disorders</i> , 2006, 21, 1892-1898.	3.9	28
210	Psychometric properties of the Spanish QoL-AD with institutionalized dementia patients and their family caregivers in Spain. <i>Aging and Mental Health</i> , 2011, 15, 775-783.	2.8	28
211	A short Scale for Evaluation of Neuropsychiatric Disorders in Parkinson's Disease: first psychometric approach. <i>Journal of Neurology</i> , 2012, 259, 2299-2308.	3.6	28
212	The Vallecas Project: A Cohort to Identify Early Markers and Mechanisms of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 181.	3.4	28
213	Comorbidity, health status, and quality of life in institutionalized older people with and without dementia. <i>International Psychogeriatrics</i> , 2013, 25, 1077-1084.	1.0	27
214	Change and predictors of quality of life in institutionalized older adults with dementia. <i>Quality of Life Research</i> , 2014, 23, 2595-2601.	3.1	27
215	Analysis of four scales for global severity evaluation in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2016, 2, 16007.	5.3	27
216	Distribution and impact on quality of life of the pain modalities assessed by the King's Parkinson's disease pain scale. <i>Npj Parkinson's Disease</i> , 2017, 3, 8.	5.3	27

#	ARTICLE	IF	CITATIONS
217	Clinical Determinants of Parkinson's Disease-associated Pain Using the King's Parkinson's Disease Pain Scale. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 545-551.	1.5	27
218	Structural correlates of apathy in Alzheimer's disease: a multimodal MRI study. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 922-930.	2.7	27
219	Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 111-117.	1.5	27
220	Exploring hyperhidrosis and related thermoregulatory symptoms as a possible clinical identifier for the dysautonomic subtype of Parkinson's disease. <i>Journal of Neurology</i> , 2019, 266, 1736-1742.	3.6	27
221	Myopathy with nemaline structures associated with HIV infection. <i>Journal of Neurology</i> , 1990, 237, 64-65.	3.6	26
222	Two questionnaires for Parkinson's disease: are the PDQ-39 and PDQL equivalent?. <i>Quality of Life Research</i> , 2007, 16, 1221-1230.	3.1	26
223	Rasch analysis of anxiety scales in Parkinson's disease. <i>Journal of Psychosomatic Research</i> , 2013, 74, 414-419.	2.6	26
224	Quality of life across three groups of older adults differing in cognitive status and place of residence. <i>Geriatrics and Gerontology International</i> , 2015, 15, 627-635.	1.5	26
225	Reprint of "Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson's disease". <i>Journal of the Neurological Sciences</i> , 2017, 374, 3-8.	0.6	26
226	Subthalamic Stimulation Improves Quality of Life of Patients Aged 61 Years or Older With Short Duration of Parkinson's Disease. <i>Neuromodulation</i> , 2018, 21, 532-540.	0.8	26
227	Intermediate scale for assessment of Parkinson's disease. Characteristics and structure. <i>Parkinsonism and Related Disorders</i> , 1995, 1, 97-102.	2.2	25
228	Prevalence and European comparison of dementia in a 75-year-old composite population in Spain. <i>Acta Neurologica Scandinavica</i> , 2011, 123, 316-324.	2.1	25
229	Quality of life (QoL) in community-dwelling and institutionalized Alzheimer's disease (AD) patients. <i>Archives of Gerontology and Geriatrics</i> , 2013, 57, 257-262.	3.0	25
230	Clinical Determinants of Health-related Quality of Life in Mexican Patients with Parkinson's Disease. <i>Archives of Medical Research</i> , 2013, 44, 110-114.	3.3	25
231	Review of Quality of Life Instruments for the Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED): Critique and Recommendations. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 1351-1357.	2.6	25
232	Minimal Clinically Important Difference for UPDRS-III in Daily Practice. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 448-450.	1.5	25
233	First comprehensive tool for screening pain in Parkinson's disease: the King's Parkinson's Disease Pain Questionnaire. <i>European Journal of Neurology</i> , 2018, 25, 1255-1261.	3.3	25
234	Influencing factors when living with Parkinson's disease: A cross-sectional study. <i>Journal of Clinical Nursing</i> , 2019, 28, 3168-3176.	3.0	25

#	ARTICLE	IF	CITATIONS
235	The Patient Card Questionnaire to Identify Wearing-off in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2007, 30, 266-275.	0.7	24
236	Barthel Index and modified Rankin Scale: Psychometric properties during medication phases in idiopathic Parkinson disease. <i>Annals of Physical and Rehabilitation Medicine</i> , 2020, 63, 500-504.	2.3	24
237	Measuring the Burden of Hospitalization in Patients with Parkinson's Disease in Spain. <i>PLoS ONE</i> , 2016, 11, e0151563.	2.5	24
238	Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson's disease patients as assessed by the Non-Motor Symptoms Questionnaire. <i>American Journal of Neurodegenerative Disease</i> , 2012, 1, 160-7.	0.1	24
239	Psychometric characteristics of the Parkinson's disease questionnaire (PDQ-39)'s Ecuadorian version. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 297-304.	2.2	23
240	Psychometric properties of the SCOPA-AUT Brazilian Portuguese version. <i>Movement Disorders</i> , 2010, 25, 205-212.	3.9	23
241	What contributes to driving ability in Parkinson's disease. <i>Disability and Rehabilitation</i> , 2010, 32, 374-378.	1.8	23
242	Infrared spectroscopic analysis of mononuclear leukocytes in peripheral blood from Alzheimer's disease patients. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 402, 2015-2021.	3.7	23
243	What impacts on the stress symptoms of Parkinson's carers? Results from the Parkinson's UK Members' Survey. <i>Disability and Rehabilitation</i> , 2014, 36, 199-204.	1.8	23
244	Improvement of dyskinesias with L-DOPA infusion in advanced Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2016, 133, 451-458.	2.1	23
245	Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Health-Related Quality of Life and Caregiver Quality of Life. <i>Movement Disorders</i> , 2018, 33, 742-749.	3.9	23
246	Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 48.	5.3	23
247	Nonmotor symptoms and health-related quality of life in early Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 166-168.	3.9	22
248	Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 361-372.	1.5	22
249	Gender gap in deep brain stimulation for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 47.	5.3	22
250	Motor Effects of REAC in Advanced Alzheimer's Disease: Results From a Pilot Trial. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 297-302.	2.6	21
251	Self-perceived health and quality of life by activity status in community-dwelling older adults. <i>Geriatrics and Gerontology International</i> , 2014, 14, 464-473.	1.5	21
252	Subthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 323-335.	2.8	21

#	ARTICLE	IF	CITATIONS
253	Cross-sectional analysis of the Parkinson's disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life. <i>Scientific Reports</i> , 2021, 11, 9611.	3.3	21
254	Comparative Incidence of Conformational, Neurodegenerative Disorders. <i>PLoS ONE</i> , 2015, 10, e0137342.	2.5	21
255	Comparison of the clinical profile of Parkinson's disease between Spanish and Cameroonian Cohorts. <i>Journal of the Neurological Sciences</i> , 2014, 336, 122-126.	0.6	20
256	Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 127-134.	1.5	20
257	Validation of a self-completed Dystonia Non-Motor Symptoms Questionnaire. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2054-2065.	3.7	20
258	Reliability and Validity of Fall Efficacy Scale-International in People with Parkinson's Disease during On- and Off-Drug Phases. <i>Parkinson's Disease</i> , 2019, 2019, 1-7.	1.1	20
259	Personalised Advanced Therapies in Parkinson's Disease: The Role of Non-Motor Symptoms Profile. <i>Journal of Personalized Medicine</i> , 2021, 11, 773.	2.5	20
260	Subclass Distribution of the Serum and Intrathecal IgG Antibody Response in Varicella-Zoster Virus Infections. <i>Journal of Infectious Diseases</i> , 1990, 162, 621-626.	4.0	19
261	Non-motor symptoms in Parkinson's disease: an underdiagnosed problem. <i>Aging Health</i> , 2006, 2, 967-982.	0.3	19
262	A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 170-174.	1.5	19
263	Parkinson's Disease Severity at 3 Years Can Be Predicted from Non-Motor Symptoms at Baseline. <i>Frontiers in Neurology</i> , 2017, 8, 551.	2.4	19
264	Improvement of impulse control disorders associated with levodopa+carbidopa intestinal gel treatment in advanced Parkinson's disease. <i>Journal of Neurology</i> , 2018, 265, 1279-1287.	3.6	19
265	Validation of a simple screening tool for early diagnosis of advanced Parkinson's disease in daily practice: the CDEPA questionnaire. <i>Npj Parkinson's Disease</i> , 2018, 4, 20.	5.3	19
266	Satisfaction with Life Scale (SLS-6): First validation study in Parkinson's disease population. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 52-57.	2.2	18
267	Measurement of Nonmotor Symptoms in Clinical Practice. <i>International Review of Neurobiology</i> , 2017, 133, 291-345.	2.0	18
268	Clinical rating scale for pantothenate kinase-associated neurodegeneration: A pilot study. <i>Movement Disorders</i> , 2017, 32, 1620-1630.	3.9	18
269	Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 479-491.	1.5	18
270	The Parkinson's Disease Composite Scale: results of the first validation study. <i>European Journal of Neurology</i> , 2018, 25, 503-511.	3.3	18



#	ARTICLE	IF	CITATIONS
271	Effects of safinamide on pain in patients with fluctuating Parkinson's disease. <i>Brain and Behavior</i> , 2021, 11, e2336.	2.2	18
272	Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson's disease. <i>Scientific Reports</i> , 2022, 12, 526.	3.3	18
273	Validation and cross-cultural adjustment of PDQL-questionnaire, Spanish version (Ecuador) (PDQL-EV). <i>Parkinsonism and Related Disorders</i> , 2004, 10, 433-437.	2.2	17
274	Longitudinal psychometric attributes, responsiveness, and importance of change: An approach using the SCOPA-Psychosocial questionnaire. <i>Movement Disorders</i> , 2008, 23, 1516-1523.	3.9	17
275	Medical, environmental and personal factors of disability in the elderly in Spain: a screening survey based on the International Classification of Functioning. <i>Gaceta Sanitaria</i> , 2011, 25, 29-38.	1.5	17
276	Rasch analysis of the International Wellbeing Index in older adults. <i>International Psychogeriatrics</i> , 2012, 24, 324-332.	1.0	17
277	Designing a new scale to measure anxiety symptoms in Parkinson's disease: item selection based on canonical correlation analysis. <i>European Journal of Neurology</i> , 2013, 20, 1198-1203.	3.3	17
278	Motor Effects of Radio Electric Asymmetric Conveyer in Alzheimer's Disease: Results from a Cross-Over Trial. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 325-332.	2.6	17
279	Modeling anxiety in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 310-316.	3.9	17
280	Quality of life of institutionalized older adults by dementia severity. <i>International Psychogeriatrics</i> , 2016, 28, 83-92.	1.0	17
281	Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 57-64.	1.5	17
282	Ultrabilitation: beyond recovery-oriented rehabilitation. <i>Disability and Rehabilitation</i> , 2019, 41, 740-745.	1.8	17
283	Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson's disease. <i>Journal of Neurology</i> , 2020, 267, 1830-1841.	3.6	17
284	How to Evaluate Validation Data. , 2012, , 16-41.		17
285	Serum Uric Acid Levels and Non-Motor Symptoms in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1003-1010.	2.8	17
286	Predictors of clinically significant quality of life impairment in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 118.	5.3	17
287	Systematic review of the effect of dopamine receptor agonists on patient health-related quality of life. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S58-S64.	2.2	16
288	Individual's perspective of local community environment and health indicators in older adults. <i>Geriatrics and Gerontology International</i> , 2013, 13, 130-138.	1.5	16

#	ARTICLE	IF	CITATIONS
289	Perceived Social Support of Older Adults in Spain. <i>Applied Research in Quality of Life</i> , 2013, 8, 183-200.	2.4	16
290	An effective environmental intervention for management of the "mirror sign"™ in a case of probable Lewy body dementia. <i>Neurocase</i> , 2013, 19, 1-13.	0.6	16
291	A Novel Rating Scale for the Measurement of Apathy in Institutionalized Persons with Dementia: The APADEM-NH. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 149-159.	1.2	16
292	Associations between chronic conditions, body functions, activity limitations and participation restrictions: a cross-sectional approach in Spanish non-clinical populations. <i>BMJ Open</i> , 2016, 6, e010446.	1.9	16
293	Self-perceived health status, gender, and work status. <i>Journal of Women and Aging</i> , 2016, 28, 386-394.	1.0	16
294	Evaluation of severity of predominantly non-dopaminergic symptoms in Parkinson's disease: The SENS-PD scale. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 39-44.	2.2	16
295	In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study. <i>Parkinsonism and Related Disorders</i> , 2021, 88, 68-75.	2.2	16
296	Parkinson's disease: quantification of disability based on the Unified Parkinson's Disease Rating Scale. <i>Neurología</i> , 2000, 15, 382-7.	0.7	16
297	Quality of life in patients with Parkinson's disease who transfer from standard levodopa to Sinemet CR: the STAR study. <i>Journal of Neurology</i> , 1998, 245, S31-S33.	3.6	15
298	ICF-Based Disability Survey in a Rural Population of Adults and Older Adults Living in Cinco Villas, Northeastern Spain: Design, Methods and Population Characteristics. <i>Neuroepidemiology</i> , 2010, 35, 72-82.	2.3	15
299	Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 169-176.	3.9	15
300	Quality of life by proxy and mortality in institutionalized older adults with dementia. <i>Geriatrics and Gerontology International</i> , 2015, 15, 38-44.	1.5	15
301	Sleep Problems Are Related to a Worse Quality of Life and a Greater Non-Motor Symptoms Burden in Parkinson's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2021, 34, 642-658.	2.3	15
302	Effects of Motor Symptom Laterality on Clinical Manifestations and Quality of Life in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1611-1620.	2.8	15
303	Impulse control and related behaviors in Parkinson's disease with dementia. <i>European Journal of Neurology</i> , 2020, 27, 944-950.	3.3	15
304	Clinical Non-Motor Phenotyping of Black and Asian Minority Ethnic Compared to White Individuals with Parkinson's Disease Living in the United Kingdom. <i>Journal of Parkinson's Disease</i> , 2021, 11, 299-307.	2.8	15
305	Specific patient-reported outcome measures for Parkinson's disease: analysis and applications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2008, 8, 401-418.	1.4	14
306	Genetic variability of the gene cluster CALHM1-3 in sporadic Creutzfeldt-Jakob disease. <i>Prion</i> , 2012, 6, 407-412.	1.8	14

#	ARTICLE	IF	CITATIONS
307	Promoting Research in Advanced Dementia: Early Clinical Results of the Alzheimer Center Reina Sofía Foundation. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 211-222.	2.6	14
308	Proposing a Parkinson's disease-specific tremor scale from the MDS-UPDRS. <i>Movement Disorders</i> , 2015, 30, 1139-1143.	3.9	14
309	Living with chronic illness scale: international validation of a new self-report measure in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2016, 2, 16022.	5.3	14
310	Self-Assessment of Disability in Parkinson's Disease: The MDS-UPDRS Part II Versus Clinician-Based Ratings. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 529-535.	1.5	14
311	Slave to the rhythm: Seasonal differences in non-motor symptoms in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 73-76.	2.2	14
312	Scales to measure parkinsonism. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 83, 289-327.	1.8	13
313	Should the SCOPA-COG be modified?: a Rasch analysis perspective. <i>European Journal of Neurology</i> , 2010, 17, 202-207.	3.3	13
314	Hoehn and Yahr Staging Scale. , 2010, , 23-25.		13
315	The Possible Clinical Predictors of Fatigue in Parkinson's Disease: A Study of 135 Patients as Part of International Nonmotor Scale Validation Project. <i>Parkinson's Disease</i> , 2011, 2011, 1-7.	1.1	13
316	Daytime apomorphine infusion combined with transdermal Rotigotine patch therapy is tolerated at 2 years: A 24-h treatment option in Parkinson's disease. <i>Basal Ganglia</i> , 2013, 3, 127-130.	0.3	13
317	Psychometric properties of the Berg balance scale in idiopathic Parkinson's disease in the drug off-phase. <i>Neurological Sciences</i> , 2018, 39, 2175-2181.	1.9	13
318	The impact of freezing of gait on functional dependency in Parkinson's disease with regard to motor phenotype. <i>Neurological Sciences</i> , 2020, 41, 2883-2892.	1.9	13
319	Leisure Activities and Quality of Life Among Older Adults in Spain. <i>Social Indicators Research Series</i> , 2015, , 163-189.	0.3	13
320	Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120148.	0.6	13
321	Independent validation of the Non motor Symptoms Scale for Parkinson's disease in Brazilian patients. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 115-119.	2.2	12
322	Validation of the Kohnen Restless Legs Syndrome Quality of Life instrument. <i>Sleep Medicine</i> , 2016, 24, 10-17.	1.6	12
323	Beyond patient-centered care: person-centered care for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2016, 2, 16019.	5.3	12
324	Predictors of short-term impulsive and compulsive behaviour after subthalamic stimulation in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1313-1318.	1.9	12

#	ARTICLE	IF	CITATIONS
325	Does the 5â€“2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5â€“2-1-positive patients in 7 countries. <i>BMC Neurology</i> , 2022, 22, 35.	1.8	12
326	Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. <i>Clinical Neuropharmacology</i> , 1997, 20, 322-37.	0.7	12
327	A Rating Scale for Gait Evaluation in Cognitive Deterioration (RSGE-CD): Validation Study. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 543-553.	2.6	11
328	Multiple sclerosis is associated with high trait anger: A caseâ€“control study. <i>Journal of the Neurological Sciences</i> , 2014, 340, 69-74.	0.6	11
329	The Neuropsychiatric Fluctuations Scale for Parkinson's Disease: A Pilot Study. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 265-272.	1.5	11
330	Discussing sexuality with Parkinsonâ€™s disease patients: a multinational survey among neurologists. <i>Journal of Neural Transmission</i> , 2019, 126, 1273-1280.	2.8	11
331	High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinsonâ€™s disease patients. <i>Journal of Neural Transmission</i> , 2019, 126, 1599-1608.	2.8	11
332	Facility ownership and mortality among older adults residing in care homes. <i>PLoS ONE</i> , 2019, 14, e0197789.	2.5	11
333	The Parkinson's Disease Sleep Scaleâ€“2 (PDSSâ€“2): Validation of the Spanish Version and Its Relationship With a Roommateâ€“Based Version. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 294-301.	1.5	11
334	Clinical Characterization of Parkinson's Disease Patients With Cognitive Impairment. <i>Frontiers in Neurology</i> , 2020, 11, 731.	2.4	11
335	Quality of life and non-motor symptoms in Parkinson's disease patients with subthreshold depression. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117109.	0.6	11
336	Cost-Effectiveness of Device-Aided Therapies in Parkinsonâ€™s Disease: A Structured Review. <i>Journal of Parkinson's Disease</i> , 2021, 11, 475-489.	2.8	11
337	The Association Between Balance, Fear of Falling and Daily Activities in Drug Phases and Different Levels of Disease Severity in Patients With Parkinson's Disease. <i>Basic and Clinical Neuroscience</i> , 2019, 10, 355-362.	0.6	11
338	Identifying Parkinsonâ€™s disease subtypes with motor and non-motor symptoms via model-based multi-partition clustering. <i>Scientific Reports</i> , 2021, 11, 23645.	3.3	11
339	Cross-Cultural Validation of the Scales for Outcomes in Parkinson's Disease-Psychosocial Questionnaire (SCOPA-PS) in Four Latin American Countries. <i>Value in Health</i> , 2009, 12, 385-391.	0.3	10
340	A Common BACE1 Polymorphism Is a Risk Factor for Sporadic Creutzfeldt-Jakob Disease. <i>PLoS ONE</i> , 2012, 7, e43926.	2.5	10
341	Dementia in Parkinson's disease: Usefulness of the pill questionnaire. <i>Movement Disorders</i> , 2013, 28, 1832-1837.	3.9	10
342	Evaluation of nocturnal hypokinesia in Parkinsonâ€™s disease using a novel patient/proxy questionnaire and correlations with objective monitoring. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 219-223.	2.2	10

#	ARTICLE	IF	CITATIONS
343	Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson's disease patients: an European multicentre survey. <i>Journal of Neural Transmission</i> , 2020, 127, 875-879.	2.8	10
344	Staging Parkinson's Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life. <i>Parkinson's Disease</i> , 2021, 2021, 1-16.	1.1	10
345	Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. <i>Journal of Personalized Medicine</i> , 2021, 11, 626.	2.5	10
346	Towards an Age-Dependent Transmission Model of Acquired and Sporadic Creutzfeldt-Jakob Disease. <i>PLoS ONE</i> , 2014, 9, e109412.	2.5	10
347	Constipation Predicts Cognitive Decline in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group. <i>Journal of Parkinson's Disease</i> , 2022, 12, 315-331.	2.8	10
348	A Patient-Centered Conceptual Model of Symptoms and Their Impact in Early Parkinson's Disease: A Qualitative Study. <i>Journal of Parkinson's Disease</i> , 2022, 12, 137-151.	2.8	10
349	Familial writer's cramp.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1985, 48, 487-487.	1.9	9
350	Comparative sensitivity of different criteria for interpreting antibody tests in cerebrospinal fluid from patients with acute viral meningitis. <i>Serodiagnosis and Immunotherapy in Infectious Disease</i> , 1990, 4, 193-199.	0.2	9
351	A protective personal factor against disability and dependence in the elderly: an ordinal regression analysis with nine geographically-defined samples from Spain. <i>BMC Geriatrics</i> , 2017, 17, 42.	2.7	9
352	Factor Analysis and Clustering of the Movement Disorder Society's "Non-Motor Rating Scale. <i>Movement Disorders</i> , 2020, 35, 969-975.	3.9	9
353	Evaluation of the metric properties of the WHODAS 2.0, WHODAS-S, and RADS in the assessment of disability in Parkinsonian patients. <i>Clinical Neurology and Neurosurgery</i> , 2020, 194, 105872.	1.4	9
354	Predictors of Loss of Functional Independence in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up and Comparison with a Control Group. <i>Diagnostics</i> , 2021, 11, 1801.	2.6	9
355	Cross-cultural evaluation of the modified Parkinson Psychosis Rating Scale across disease stages. <i>Movement Disorders</i> , 2010, 25, 1391-1398.	3.9	8
356	Which factors are associated with mortality in institutionalized older adults with dementia?. <i>Archives of Gerontology and Geriatrics</i> , 2014, 59, 522-527.	3.0	8
357	Effect of anticholinergic drugs on cognitive impairment in the elderly. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2015, 8, 35-43.	0.3	8
358	Validation of the multimodal assessment of capacities in severe dementia: a novel cognitive and functional scale for use in severe dementia. <i>Journal of Neurology</i> , 2015, 262, 1198-1208.	3.6	8
359	Associative participation of older adults and subjective quality of life: exploring self-selection bias. <i>Ageing and Society</i> , 2015, 35, 1343-1363.	1.7	8
360	Drivers: A Biologically Contextualized, Cross-Inferential View of the Epidemiology of Neurodegenerative Disorders. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 1003-1022.	2.6	8

#	ARTICLE	IF	CITATIONS
361	Extensive validation study of the Parkinson's Disease Composite Scale. <i>European Journal of Neurology</i> , 2019, 26, 1281-1288.	3.3	8
362	Residential Environment and Health Conditions Among Older-Adults in Community-Dwelling in Spain: What Influences Quality of Life?. <i>International Perspectives on Aging</i> , 2016, , 149-174.	0.4	8
363	Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 108.	5.3	8
364	Conversion to controlled-release levodopa/carbidopa treatment and quality of life as measured by the Nottingham Health Profile. <i>The STAR Study Group. Neurología</i> , 1999, 14, 338-43.	0.7	8
365	Health-related quality of life in Parkinson's disease: outcomes of the therapeutic interventions. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2001, 1, 99-108.	1.4	7
366	Sleep Duration and Time during Different Periods of the Day and Night in Patients with Advanced Parkinson's Disease Receiving Adjunctive Ropinirole Prolonged Release. <i>Parkinson's Disease</i> , 2011, 2011, 1-8.	1.1	7
367	Is the Parkinson anxiety scale comparable across raters?. <i>Movement Disorders</i> , 2015, 30, 545-551.	3.9	7
368	Short-term association between road traffic noise and healthcare demand generated by Parkinson's disease in Madrid, Spain. <i>Gaceta Sanitaria</i> , 2018, 32, 553-558.	1.5	7
369	Rating Scales for Movement Disorders With Sleep Disturbances: A Narrative Review. <i>Frontiers in Neurology</i> , 2018, 9, 435.	2.4	7
370	A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice. <i>Brain Sciences</i> , 2020, 10, 176.	2.3	7
371	Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson's disease. <i>BMC Neurology</i> , 2021, 21, 477.	1.8	7
372	Handbook of Non-Motor Symptoms in Parkinson's Disease. , 2011, , .		6
373	Instruments for holistic assessment of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2013, 120, 559-564.	2.8	6
374	Independent Validation of the SEND-PD and Correlation with the MDS-UPDRS Part IA. <i>Parkinson's Disease</i> , 2014, 2014, 1-5.	1.1	6
375	PREDICTING THE EQ-5D FROM THE PARKINSON'S DISEASE QUESTIONNAIRE PDQ-8 USING MULTI-DIMENSIONAL BAYESIAN NETWORK CLASSIFIERS. <i>Biomedical Engineering - Applications, Basis and Communications</i> , 2014, 26, 1450015.	0.6	6
376	Etiologic Framework for the Study of Neurodegenerative Disorders as Well as Vascular and Metabolic Comorbidities on the Grounds of Shared Epidemiologic and Biologic Features. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 138.	3.4	6
377	Restless legs syndrome - the under-recognised non-motor burden: a questionnaire-based cohort study. <i>Postgraduate Medicine</i> , 2019, 131, 473-478.	2.0	6
378	<p>&lt;p>Validation study of the Parkinson's Fatigue Scale in advanced Parkinson's disease</p>. <i>Patient Related Outcome Measures</i> , 2019, Volume 10, 141-152.	1.2	6

#	ARTICLE	IF	CITATIONS
379	Applications of the European Parkinson's Disease Association sponsored Parkinson's Disease Composite Scale (PDCS). <i>Npj Parkinson's Disease</i> , 2019, 5, 26.	5.3	6
380	Non-motor symptom burden in patients with Parkinson's disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort. <i>Scientific Reports</i> , 2020, 10, 16893.	3.3	6
381	Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson's disease. <i>Brain and Behavior</i> , 2021, 11, e02086.	2.2	6
382	The New Satisfaction with Life and Treatment Scale (SLTS-7) in Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 453-464.	2.8	6
383	P2.149 Efficacy of apomorphine infusion on mood and depression aspects of non-motor symptoms in advanced Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S130.	2.2	5
384	Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 1329-1342.	2.8	5
385	Guide to Assessment Scales in Parkinson's Disease. , 2014, , .		5
386	The Parkinson's Disease Composite Scale Is Adequately Responsive to Acute Levodopa Challenge. <i>Parkinson's Disease</i> , 2019, 2019, 1-8.	1.1	5
387	Psychometric Properties of the Apathy Scale in Advanced Parkinson's Disease. <i>Parkinson's Disease</i> , 2019, 2019, 1-8.	1.1	5
388	Interpretation of health-related quality of life outcomes in Parkinson's disease from the EARLYSTIM Study. <i>PLoS ONE</i> , 2020, 15, e0237498.	2.5	5
389	Toward eScales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 208-214.	1.5	5
390	Falls Predict Acute Hospitalization in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, , 1-20.	2.8	5
391	Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson's Disease Patients: A 2-Year Follow-Up Study. <i>Diagnostics</i> , 2022, 12, 1147.	2.6	5
392	Falling upward with Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2017, 3, 29.	5.3	4
393	Dietary Variations in a Multiethnic Parkinson's Disease Cohort and Possible Influences on Nonmotor Aspects: A Cross-Sectional Multicentre Study. <i>Parkinson's Disease</i> , 2018, 2018, 1-9.	1.1	4
394	Rating Scales in Movement Disorders. , 2017, , 65-75.		4
395	Validation of the Thai Version of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale. <i>Journal of Movement Disorders</i> , 2022, 15, 151-155.	1.3	4
396	Clinical Gait and Balance Scales for Parkinson's Disease. <i>Journal of the Neurological Sciences</i> , 2004, 221, 125.	0.6	3

#	ARTICLE	IF	CITATIONS
397	Independent and Complementary Validation of the QUIPâ€RS in Advanced Parkinson's Disease. Movement Disorders Clinical Practice, 2018, 5, 341-342.	1.5	3
398	Which Scale Best Detects Treatment Response of Tremor in Parkinsonism?. Journal of Parkinson's Disease, 2020, 10, 275-282.	2.8	3
399	Assessment tools for non-motor symptoms of Parkinsonâ€™s disease. , 2009, , 47-58.		3
400	Prevalence of Advanced Parkinsonâ€™s Disease in Patients Treated in the Hospitals of the Spanish National Healthcare System: The PARADISE Study. Brain Sciences, 2021, 11, 1557.	2.3	3
401	Parkinsonâ€™s Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Parkinson's Disease, 2022, 12, 935-955.	2.8	3
402	MNCD: A New Tool for Classifying Parkinsonâ€™s Disease in Daily Clinical Practice. Diagnostics, 2022, 12, 55.	2.6	3
403	CLUSTERS OF SHINGLES. Lancet, The, 1985, 326, 1433-1434.	13.7	2
404	I.P2 Prevalence of non motor symptoms in Parkinson's Disease: An international survey using NMSQuest in 525 patients. Parkinsonism and Related Disorders, 2006, 12, 21.	2.2	2
405	2.135 CHARACTERISING NON MOTOR PATTERNS OF EARLY MORNING OFF PERIODS IN PARKINSON'S DISEASE: AN INTERNATIONAL STUDY. Parkinsonism and Related Disorders, 2012, 18, S110.	2.2	2
406	Factores determinantes del inicio de tratamiento con levodopa/carbidopa/entacapona en pacientes espaÃ±oles con enfermedad de Parkinson. NeurologÃa, 2014, 29, 153-160.	0.7	2
407	Assessing health-related quality of life with the SCOPA-PS in French individuals with Parkinson's disease having undergone DBS-STN: A validation study. Revue Neurologique, 2016, 172, 281-288.	1.5	2
408	Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. Movement Disorders, 2018, 33, 499-500.	3.9	2
409	In Support of Electronic Versions of <scp>Movement Disorder Society</scp> Rating Scales. Movement Disorders, 2021, 36, 270-271.	3.9	2
410	Non-motor symptoms and health-related quality of life. , 2009, , 309-320.		2
411	Validation of the QUEST for German-speaking countries. International Journal of Neuroscience, 2016, 126, 127-34.	1.6	2
412	Multi-domain Scales. , 2014, , 13-23.		2
413	Scales that Evaluate Specific Non-motor Disorders. , 2014, , 49-65.		2
414	Validation of the Arabic Version of the Movement Disorder Societyâ€™Unified Parkinson's Disease Rating Scale. Movement Disorders, 2022, 37, 826-841.	3.9	2



#	ARTICLE	IF	CITATIONS
415	Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. <i>Diagnostics</i> , 2021, 11, 2380.	2.6	2
416	Dual detection of antibody to both herpes simplex and varicella-zoster viruses in cerebrospinal fluid: Cross reactivity or dual infection?. <i>Journal of Neurology</i> , 1996, 243, 618-619.	3.6	1
417	1.014 Non-motor symptoms in akinesia dominant versus other phenotypes in Parkinson's disease (PD): Results from the international PD non-motor symptoms scale study. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S31.	2.2	1
418	1.144 Changes in sexual interest and function in patients with Parkinson's disease: Focus on hypersexuality. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S44-S45.	2.2	1
419	Rating Scales in Movement Disorders. , 2010, , 8-16.		1
420	Quality of Life of Community-Dwelling Older Adults in Spain. <i>Community Quality-of-life and Well-being</i> , 2017, , 269-286.	0.2	1
421	Features and impact of missing values in the association of self-rated health with mortality in care homes: a longitudinal study. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 111.	2.4	1
422	Embarrassment and Shame in People With Parkinson's Disease: A New Tool for Self-Assessment. <i>Frontiers in Neurology</i> , 2020, 11, 779.	2.4	1
423	Cognition and Neuropsychiatric Symptoms. , 2014, , 67-89.		1
424	CHAPTER 1. Parkinson's Disease: Symptoms, Unmet Needs and New Therapeutic Targets. <i>RSC Drug Discovery Series</i> , 2013, , 3-25.	0.3	1
425	Quality of Life Scales. , 2014, , 91-102.		1
426	Motor Impairment and Disability Scales. , 2014, , 31-42.		1
427	1.126 Non-motor symptoms in akinesia dominant versus other phenotypes in Parkinson's disease (PD): Results from the international PD non-motor symptoms scale study. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S40.	2.2	0
428	1.152 Dribbling of saliva in Parkinson's disease: Clinical correlations. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S47.	2.2	0
429	2.003 Clinimetrics. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S87.	2.2	0
430	2.262 Adherence to antiparkinson medication in a multi-centre European study.. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S115.	2.2	0
431	3.420 Differential effect of the Parkinson's disease non-motor symptoms on patients' health-related quality of life. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S185.	2.2	0
432	3.508 SCOPA-COG Brazilian Version: psychometric attributes. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S189.	2.2	0

#	ARTICLE	IF	CITATIONS
433	PND44 EVALUATION OF THE IMPACT OF PARKINSON'S DISEASE SYMPTOMS ON HEALTH-RELATED QUALITY OF LIFE. PD-QOL STUDY. Value in Health, 2009, 12, A374.	0.3	0
434	PMH47 Validity of the Q10 Questionnaire for Diagnosis of Wearing-off Phenomena in Parkinson's Disease: A Q10 Study. Value in Health, 2011, 14, A295.	0.3	0
435	An in-Depth Look at the Non Motor Symptom Scale. , 2011, , 37-43.		0
436	Is AD a homogeneous nosologic entity? Yes. Journal of Neural Transmission, 2013, 120, 1467-1473.	2.8	0
437	Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease. Neurología (English Edition), 2014, 29, 153-160.	0.4	0
438	A review of "Validity and Validation in Social, Behavioral, and Health Sciences", Bruno D. Zumbo and Eric K.H. Chan Editors. Applied Research in Quality of Life, 2015, 10, 547-549.	2.4	0
439	Response to letter by Saenz-Farret et al. on "Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations", Movement Disorders, 2017, 32, 482-482.	3.9	0
440	Cross-Fertilization of Studies in Neurodegeneration. , 2017, 07, .		0
441	Reply: Hoehn and Yahr stage 3 and Postural stability item in the Movement Disorder Society's Unified Parkinson's Disease Rating Scale. Movement Disorders, 2018, 33, 1189-1190.	3.9	0
442	Clinimetrics of the Freezing of Gait Questionnaire for Parkinson Disease During the "off" State. Basic and Clinical Neuroscience, 2021, 12, 69-78.	0.6	0
443	Quality of Life of Older People with Dementia. International Handbooks of Quality-of-life, 2021, , 135-146.	0.5	0
444	Psychometric features of brief pain inventory for Parkinson's disease during medication states. Disability and Rehabilitation, 2021, , 1-6.	1.8	0
445	Assessing Non-Motor Symptoms: An Overview of Scales and Questionnaires. , 2011, , 27-35.		0
446	Global Severity Assessments. , 2014, , 25-29.		0
447	Comprehensive Non-motor Symptoms Assessments. , 2014, , 43-47.		0
448	Scales for Measuring Parkinsonism in Demented Patients. , 2014, , 117-128.		0
449	Quality of Life in Parkinson's Disease. , 2017, , 165-180.		0
450	Clinimetrics of the Freezing of Gait Questionnaire for Parkinson Disease During the "off" State. Basic and Clinical Neuroscience, 2021, 12, 69-78.	0.6	0